Please select the eligibility criteria that correspond to the clinical trial below.
Title: Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Brief Summary: Painful diabetic peripheral neuropathy (DPN) affects more than 5.5 million people with diabetes. People with painful DPN have trouble sleeping, participating in social events, and conducting daily activities such as going to the store. Several prescription medications are available for the treatment of DPN symptoms, but none work perfectly and all have side effects that may be difficult for some patients.

When patients report their symptoms and side effects to their doctor, they provide the doctor with important information to help them make adjustments to treatment that will help with symptoms and that the patient can tolerate in terms of side effects. In some cases, doctors may encourage patients to make these changes on their own at home based on their experience with therapy. However, patients may have a long time between visits to their doctor and may have trouble describing their symptoms to their doctor during a brief 10 to 15 minute visit.

This clinical trial explores the possibility of computerized telephone calls to patients (Interactive Voice Response, IVR, technology) to gather information about treatment experiences that can then be reported to the doctor or used to guide patients to make changes in how they take the medication. It addresses the following question: Can routinely asking patients about their experiences with medications and using that information to encourage clinically appropriate titration improve patient quality of life?

The investigators hypothesize that systematic collection and feedback of information about DPN treatment preferences and experience from newly treated patients to their primary care physician will facilitate treatment changes that improve patient outcomes


Options:
A: Inclusion Criteria:

* All patients newly prescribed medication to treat diabetic peripheral neuropathy symptoms.

Exclusion Criteria:

* Patients with any evidence of use of diabetic peripheral neuropathy study medications.
* Patients with evidence of gestational diabetes (ICD-9: 648.8) due to variation in treatment and monitoring for women who are pregnant.
* Patients who simultaneously received a new diagnosis for depression or seizure conditions
B: Inclusion Criteria:

* (Suspected) diagnosis of neuralgic amyotrophy
* In subacute or chronic phase of neuralgic amyotrophy (\>2 months after attack onset)
* Right-handed
* Neuralgic amyotrophy predominantly present in right upper extremity
* Presence of scapular dyskinesia

Exclusion Criteria:

* Patients in the acute phase of NA (characterized by severe pain and inflammation of the brachial plexus)
* (Prior) NA attacks of the lumbosacral plexus or the left upper extremity
* Sever comorbidity
* Any (bio)mechanical constraints of the shoulder girdle
* Any other central nervous system, neurological, or neuromuscular disorder
C: Inclusion Criteria:

* Be experiencing a permanent disability of at least 6 months that limits mobility sufficiently to require use of a wheelchair as the primary method of mobility outside the home
* Have not been moderately to vigorously physically active for the past 6 months
* Be willing to attend the educational workshop
* Receive physician approval for participation

Exclusion criteria include:

* Presence of medical conditions such as uncontrolled cardiovascular problems that the patient's physician identifies as being contraindicated for exercise
* Pregnancy or planning to become pregnant
D: Inclusion Criteria:

* Able to provide informed consent
* Genetically proven DM1
* Suffering from severe fatigue (CIS fatigue \>35
* Able to walk independently

Exclusion Criteria:

* Neurological or orthopaedic co-morbidity interfering with the interventions or possibly influencing outcomes.
* Use of psychotropic drugs (except Modafinil, Ritalin and antidepressants where the dosing regimen has been stable for at least 12 months prior to screening). If the doses of Modafinil or Ritalin increase during the 10 months of the intervention then the participant will be excluded.
* Severe depression as screening (judged as meeting DSM-IV criteria for a depressive episode).
* Participation in another clinical trial of an investigational medicinal product (CTIMP) or other interventional study considered to influence outcomes being evaluated in OPTIMISTIC.
* Unable to complete study questionnaires.
* Subject participating in another clinical trial (other than observational trials and registries) concurrently or within 30 days prior to screening for entry into this study.

Answer: A